## Bictegravir-<sup>15</sup>N,d<sub>2</sub>

HY-17605S

452.39

Others

Analysis.

 $C_{21}H_{16}D_{2}F_{3}N_{2}^{15}NO_{5}$ 

Isotope-Labeled Compounds

Cat. No.:

Target:

Pathway:

Storage:

Molecular Formula:

Molecular Weight:

BIOLOGICAL ACTIVITY	
BIOLOGICAL ACTIVITY	
Description	Bictegravir- <sup>15</sup> N,d <sub>2</sub> (GS-9883- <sup>15</sup> N,d <sub>2</sub> ) is the <sup>15</sup> N and deuterium labeled Bictegravir (HY-17605) <sup>[1]</sup> . Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC <sub>50</sub> of 7.5 nM <sup>[2]</sup> .
IC <sub>50</sub> & Target	IC50: 7.5 nM (HIV-1 integrase) <sup>[1]</sup>
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . Bictegravir (BIC) inhibits the strand transfer activity with an IC <sub>50</sub> of 7.5± 0.3 nM. Relative to its inhibition of strand transfer activity, Bictegravir is a much weaker inhibitor of 3'-processing activity of HIV-1 IN, with an IC <sub>50</sub> of 241±51 nM. Bictegravir enhances the accumulation of 2-LTR circles ~5-fold relative to the mock-treated control and reduces the amount of authentic integration products in infected cells by 100-fold. Bictegravir potently inhibits HIV-1 replication in both MT-2 and MT-4 cells with EC <sub>50</sub> s of 1.5 and 2.4 nM, respectively. Bictegravir exhibits potent antiviral effects in both primary CD4 <sup>+</sup> T lymphocytes and monocyte-derived macrophages, with EC <sub>50</sub> s of 1.5±0.3 nM and 6.6±4.1 nM, respectively, which are comparable to values obtained in T-cell lines <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Please store the product under the recommended conditions in the Certificate of

## REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

9 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

## RedChemExpress